Preferred Share Offering

In keeping with Verseon’s philosophy of approaching problems from new perspectives, we are also pioneering the use of blockchain technology to create a new funding model for the 21st century.

In 2019, we plan to launch a preferred share offering to accelerate the development of our diverse drug pipeline of novel drug candidates.

Our offering will be backed by an EU prospectus. The offering will use the technology and services of our blockchain fintech subsidiary BlockRules Ltd. to enforce regulatory compliance across multiple jurisdictions.

Each security will be a form of preferred share that grants its holder rights to a percentage of Verseon’s future drug program revenues.

We will initially conduct a private offering, followed by a public sale upon approval of the prospectus.

To keep informed, please subscribe below

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen